Search

Search Results

1. Pre-treatment ⁶⁸ Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to ¹⁷⁷Lu-PSMA-I&T Therapy and Patient Survival

   Purpose

   To assess the prognostic value of pre-treatment [ ⁶⁸ Ga]Ga-PSMA-11 PET/CT and other baseline clinical characteristics in predicting prostate...

   Roya Eisazadeh, Seyed Ali Mirshahvalad, ... Mohsen Beheshti in Molecular Imaging and Biology

   Article Open access 15 February 2024
   

2. Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer

   Purpose

   The purpose of this study was to assess whether total-body [ ⁶⁸ Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with...

   Yining Wang, Zijun Chen, ... Jianjun Liu in European Journal of Nuclear Medicine and Molecular Imaging

   Article 14 August 2023
   

3. Evaluation of [⁶⁸ Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria

   Background

   PSMA PET/CT is the recommended imaging test in cases with prostate-specific antigen (PSA) recurrence after primary therapy of prostate...

   Daniel Koehler, Markus Sauer, ... Christoph Berliner in EJNMMI Research

   Article Open access 09 October 2022
   

4. A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [⁶⁸Ga]Ga-PSMA-11

   Background

   The current generation of radiolabeled PSMA-targeting therapeutic agents is limited by prominent salivary gland binding, which results in...

   Steve S. Huang, Frank P. DiFilippo, ... Warren D. Heston in EJNMMI Radiopharmacy and Chemistry

   Article Open access 30 January 2024
   

5. Evaluating the biodistribution for [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis

   Background

   Liver uptake in [ ⁶⁸ Ga]Ga-PSMA-11 PET is used as an internal reference in addition to clinical parameters to select patients for [ ¹⁷⁷ Lu]Lu-P...

   Cristina E. Popescu, Boya Zhang, ... Alexander Maurer in EJNMMI Research

   Article Open access 05 April 2024
   

6. The superior detection rate of total-body [⁶⁸Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [⁶⁸Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy

   Background and purpose

   [ ⁶⁸ Ga]Ga-PSMA PET imaging has been extensively utilized for the detection of biochemical recurrence (BCR) in prostate cancer....

   Yining Wang, Liang Dong, ... Ruohua Chen in European Journal of Nuclear Medicine and Molecular Imaging

   Article 22 March 2024
   

7. Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [⁶⁸Ga]Ga-PSMA-11 PET/CT imaging: quantitative analysis of [⁶⁸Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs

   Purpose

   This study aimed to quantitatively assess [ ⁶⁸ Ga]Ga-PSMA-11 uptake in pathological lesions and normal organs in prostate cancer using the...

   Ruohua Chen, Yee Ling Ng, ... Jianjun Liu in European Journal of Nuclear Medicine and Molecular Imaging

   Article 27 October 2023
   

8. Automated radiolabelling of [⁶⁸Ga]Ga-PSMA-11 (gallium (⁶⁸Ga)-gozetotide) using the Locametz® kit and two generators

   Background

   Steps have been taken by pharmaceutical companies to obtain marketing authorisation of PSMA ligands in the European Union. Since December...

   Elke A. van Brandwijk, Else A. Aalbersberg, ... Jeroen J. M. A. Hendrikx in EJNMMI Radiopharmacy and Chemistry

   Article Open access 17 April 2024
   

9. A prospective comparative study of [⁶⁸Ga]Ga-RM26 and [⁶⁸Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer

   Purpose

   Prostate-specific membrane antigen (PSMA)–based PET/CT imaging has limitations in the diagnosis of prostate cancer (PCa). We recruited 207...

   **aomei Gao, Yongxiang Tang, ... Shuo Hu in European Journal of Nuclear Medicine and Molecular Imaging

   Article 22 February 2023
   

10. Diverse PSMA expression in primary prostate cancer: reason for negative [⁶⁸Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens

    Purpose

    The purpose of this study was to immunohistochemically validate the primary tumor PSMA expression in prostate cancer (PCa) patients imaged...

    Wojciech Cytawa, Stefan Kircher, ... Andreas K. Buck in European Journal of Nuclear Medicine and Molecular Imaging

    Article 12 May 2022
    

11. The image quality and feasibility of solitary delayed [⁶⁸ Ga]Ga-PSMA-11 PET/CT using long field-of-view scanning in patients with prostate cancer

    Background

    Previous studies have demonstrated that delayed [ ⁶⁸  Ga]Ga-PSMA PET/CT imaging improves lesion detection compared to early [ ⁶⁸ Ga]Ga-PSMA...

    **aofeng Yu, Lian Xu, ... Yumei Chen in EJNMMI Research

    Article Open access 06 February 2024
    

12. A prospective head-to-head comparison of [⁶⁸Ga]Ga-P16-093 and [⁶⁸Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

    Purpose

    We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [ ⁶⁸ Ga]Ga-P16-093 and [ ⁶⁸ Ga]Ga-PSMA-11, in the...

    Guochang Wang, Linlin Li, ... Zhaohui Zhu in European Journal of Nuclear Medicine and Molecular Imaging

    Article 26 May 2023
    

13. [⁶⁸Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA PET/CT

    Purpose

    To compare the potential efficiency of [ ⁶⁸ Ga]Ga-LNC1007 with 2-[ ¹⁸ F]FDG/[ ⁶⁸ Ga]Ga-PSMA PET/CT for detecting renal cell carcinoma (RCC) and to...

    Rong Lin, Chao Wang, ... Weibing Miao in European Journal of Nuclear Medicine and Molecular Imaging

    Article 20 September 2023
    

14. A convolutional neural network–based system for fully automatic segmentation of whole-body [⁶⁸Ga]Ga-PSMA PET images in prostate cancer

    Purpose

    The aim of this study was development and evaluation of a fully automated tool for the detection and segmentation of mPCa lesions in...

    Esmail Jafari, Amin Zarei, ... Majid Assadi in European Journal of Nuclear Medicine and Molecular Imaging

    Article 14 December 2023
    

15. Comparison of parametric imaging and SUV imaging with [⁶⁸ Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer

    Purpose

    Standardized uptake value (SUV) has been prevalently used to measure [ ⁶⁸ Ga]Ga-PSMA-11 activity in prostate cancer, but it is susceptible to...

    Ruohua Chen, Yee Ling Ng, ... Jianjun Liu in European Journal of Nuclear Medicine and Molecular Imaging

    Article 04 October 2023
    

16. Automated segmentation of lesions and organs at risk on [⁶⁸Ga]Ga-PSMA-11 PET/CT images using self-supervised learning with Swin UNETR

    Background

    Prostate-specific membrane antigen (PSMA) PET/CT imaging is widely used for quantitative image analysis, especially in radioligand therapy...

    Elmira Yazdani, Najme Karamzadeh-Ziarati, ... Saeed Reza Kheradpisheh in Cancer Imaging

    Article Open access 29 February 2024
    

17. Role of [⁶⁸Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer

    Purpose

    The aim of this study is to investigate the role of [ ⁶⁸ Ga]Ga-PSMA-11 PET radiomics for the prediction of post-surgical International Society...

    Samuele Ghezzo, Paola Mapelli, ... Maria Picchio in European Journal of Nuclear Medicine and Molecular Imaging

    Article 18 March 2023
    

18. Deep learning–based whole-body characterization of prostate cancer lesions on [⁶⁸Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence

    Purpose

    The automatic segmentation and detection of prostate cancer (PC) lesions throughout the body are extremely challenging due to the lesions’...

    Bingsheng Huang, Qinqin Yang, ... Chang**g Zuo in European Journal of Nuclear Medicine and Molecular Imaging

    Article 05 December 2023
    

19. Meta-analysis of ¹⁸ F-PSMA-1007 PET/CT, ¹⁸ F-FDG PET/CT, and ⁶⁸Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer

    Objective

    To compare ¹⁸  F-PSMA-1007 PET/CT, ¹⁸  F-FDG PET/CT and ⁶⁸ Ga-PSMA PET/CT in the diagnostic value of prostate cancer.

    Method

    The Chinese and...

    Wenxiao Yu, Ming Zhao, ... Jun Guo in Cancer Imaging

    Article Open access 21 August 2023
    

20. Comparison of tracer kinetic models for ⁶⁸Ga-PSMA-11 PET in intermediate-risk primary prostate cancer patients

    Background

    ⁶⁸ Ga-PSMA-11 positron emission tomography enables the detection of primary, recurrent, and metastatic prostate cancer. Regional...

    Nathaniel J. Smith, Mark A. Green, ... Gary D. Hutchins in EJNMMI Research

    Article Open access 10 January 2024